Turk Ilac ve Serum Sanayi AS
IST:TRILC.E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Changzhou Xiangming Intelligent Drive System Corporation
SZSE:301226
|
CN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (8.2), the stock would be worth ₺37.85 (98% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.1 | ₺19.1 |
0%
|
| 3-Year Average | 8.2 | ₺37.85 |
+98%
|
| 5-Year Average | 10.7 | ₺49.71 |
+160%
|
| Industry Average | 17.5 | ₺81.08 |
+325%
|
| Country Average | 11.5 | ₺53.21 |
+179%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| TR |
T
|
Turk Ilac ve Serum Sanayi AS
IST:TRILC.E
|
3.1B TRY | 4.1 | -5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 28.4 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 16.9 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.5 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 16.1 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 9.7 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 7.5 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 7.1 | 16.9 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 7 |
| Median | 11.5 |
| 70th Percentile | 21.5 |
| Max | 147 825.3 |
Other Multiples
Turk Ilac ve Serum Sanayi AS
Glance View
Türk Ilaç ve Serum Sanayi AS engages in the manufacture of medical drugs. The main activity of the Company is to manufacture and sell all kinds of tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids and other chemical substances. The firm also acts as the representative or sales agency of other domestic and foreign pharmaceutical companies, as well as importing and marketing veterinary, cosmetics and pesticides. Turk Ilac manufactures in accordance with Current Good Manufacturing (GMP) and Good Laboratory Practice (GLP) principles with its approximately 300 employees in its facilities on a total area of 56.000 square meters in the Ankara - Akyurt region.
